PH12019500638A1 - Composite formed into single layer, comprising candesartan and amlodipine - Google Patents

Composite formed into single layer, comprising candesartan and amlodipine

Info

Publication number
PH12019500638A1
PH12019500638A1 PH12019500638A PH12019500638A PH12019500638A1 PH 12019500638 A1 PH12019500638 A1 PH 12019500638A1 PH 12019500638 A PH12019500638 A PH 12019500638A PH 12019500638 A PH12019500638 A PH 12019500638A PH 12019500638 A1 PH12019500638 A1 PH 12019500638A1
Authority
PH
Philippines
Prior art keywords
candesartan
amlodipine
single layer
composite formed
pharmaceutically acceptable
Prior art date
Application number
PH12019500638A
Other languages
English (en)
Inventor
Dae Young Jeong
Min Kwan Cho
Shin Jung Park
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of PH12019500638A1 publication Critical patent/PH12019500638A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH12019500638A 2016-09-30 2019-03-22 Composite formed into single layer, comprising candesartan and amlodipine PH12019500638A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160126879A KR101769293B1 (ko) 2016-09-30 2016-09-30 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제
PCT/KR2017/009098 WO2018062685A1 (ko) 2016-09-30 2017-08-21 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제

Publications (1)

Publication Number Publication Date
PH12019500638A1 true PH12019500638A1 (en) 2019-11-04

Family

ID=59760539

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019500638A PH12019500638A1 (en) 2016-09-30 2019-03-22 Composite formed into single layer, comprising candesartan and amlodipine

Country Status (5)

Country Link
JP (1) JP6758488B2 (ja)
KR (1) KR101769293B1 (ja)
CN (1) CN109789099A (ja)
PH (1) PH12019500638A1 (ja)
WO (1) WO2018062685A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110638764A (zh) * 2019-09-23 2020-01-03 珠海润都制药股份有限公司 一种坎地沙坦酯速释小丸
KR102304910B1 (ko) 2021-01-11 2021-09-27 알리코제약(주) 칸데사르탄을 함유하는 안정한 약학적 조성물
CN117538462B (zh) * 2024-01-10 2024-03-26 地奥集团成都药业股份有限公司 一种氨氯地平贝那普利胶囊有关物质的检测方法
CN117538461B (zh) * 2024-01-10 2024-03-26 地奥集团成都药业股份有限公司 一种盐酸贝那普利片有关物质的检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI494134B (zh) * 2006-06-20 2015-08-01 Siegfried Generics Int Ag 含有坎地沙坦酯的組成物、錠劑和顆粒及該錠劑的製造方法
US20100041644A1 (en) * 2006-11-28 2010-02-18 Laboratorios Liconsa, S. A. Stabilized solid pharmaceutical composition of candesartan cilexetil
CN101612151B (zh) * 2008-06-25 2012-09-12 浙江华海药业股份有限公司 含有坎地沙坦酯或坎地沙坦氢氯噻嗪的固体口服制剂及其制备方法
JP2013014547A (ja) * 2011-07-05 2013-01-24 Elmed Eisai Kk カンデサルタンシレキセチルを安定化した組成物及びその製造方法
CN102688236B (zh) * 2012-06-06 2014-03-26 石药集团中诺药业（石家庄）有限公司 一种坎地沙坦酯氨氯地平片剂组合物及其制备方法
WO2014058046A1 (ja) * 2012-10-12 2014-04-17 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤
JP5790965B2 (ja) * 2012-10-12 2015-10-07 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
WO2016122256A1 (ko) * 2015-01-30 2016-08-04 씨제이헬스케어 주식회사 칸데사르탄 및 암로디핀을 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
CN109789099A (zh) 2019-05-21
JP6758488B2 (ja) 2020-09-23
KR101769293B1 (ko) 2017-08-30
JP2019529486A (ja) 2019-10-17
WO2018062685A1 (ko) 2018-04-05

Similar Documents

Publication Publication Date Title
PH12019500638A1 (en) Composite formed into single layer, comprising candesartan and amlodipine
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX362838B (es) Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
PH12017502249A1 (en) Tofacitinib orally disintegrating tablets
PH12017500388A1 (en) Tadalafil oral dispersible film and preparing method thereof
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
MX365216B (es) Forma de dosificacion por via oral de difenhidramina de disolucion rapida.
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof
WO2016122289A3 (ko) 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물
JO3435B1 (ar) تركيبة دوائية صلبة تحتوي على أملوديبن ولوسارتان
MX2015003956A (es) Composicion farmaceutica que comprende bromuro de pinaverio micronizado y simeticona.
MX370184B (es) Composición farmacéutica que comprende fingolimod.
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
PH12016502527A1 (en) Stabilized desmopressin
WO2016108507A3 (ko) 멜라토닌 및 설트랄린을 포함하는 경구용 복합정제
WO2016126115A3 (en) Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof
PH12018501392A1 (en) Pharmaceutical composite preparation
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
PH12018550075A1 (en) An oral osmotic pharmaceutical composition of vildagliptin
PH12019500779A1 (en) Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
UA109242U (uk) Стабільна фармацевтична композиція, що містить інгібітор протеасом